Literature DB >> 17704511

A Gne knockout mouse expressing human GNE D176V mutation develops features similar to distal myopathy with rimmed vacuoles or hereditary inclusion body myopathy.

May Christine V Malicdan1, Satoru Noguchi, Ikuya Nonaka, Yukiko K Hayashi, Ichizo Nishino.   

Abstract

Distal myopathy with rimmed vacuoles (DMRV) or hereditary inclusion body myopathy (hIBM) is an early adult-onset distal myopathy caused by mutations in the UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase (GNE) gene which encodes for a bifunctional enzyme involved in sialic acid biosynthesis. It is pathologically characterized by the presence of rimmed vacuoles (RVs), especially in atrophic fibers, which also occasionally contain congophilic materials that are immunoreactive to beta-amyloid, lysosomal proteins, ubiquitin and tau proteins. To elucidate the pathomechanism of this myopathy and to explore treatment options, we generated a mouse model of DMRV/hIBM. We knocked out the Gne gene in mice but this resulted in embryonic lethality. We therefore generated a transgenic mouse that expressed the human GNE D176V mutation, which is one of the most prevalent mutations among Japanese DMRV patients, and crossed this with Gne(+/-) mice to obtain Gne(-/-)hGNED176V-Tg. Interestingly, these mice exhibit marked hyposialylation in serum, muscle and other organs. Reduction in motor performance in these mice can only be seen from 30 weeks of age. A compelling finding is the development of beta-amyloid deposition in myofibers by 32 weeks, which clearly precedes RV formation at 42 weeks. These results show that the Gne(-/-)hGNED176V-Tg mouse mimics the clinical, histopathological and biochemical features of DMRV/hIBM, making it useful for understanding the pathomechanism of this myopathy and for employing different strategies for therapy. Our findings underscore the notion that hyposialylation plays an important role in the pathomechanism of DMRV/hIBM.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17704511     DOI: 10.1093/hmg/ddm220

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  55 in total

1.  Clinical features, lectin staining, and a novel GNE frameshift mutation in hereditary inclusion body myopathy.

Authors:  N C Voermans; M Guillard; R Doedée; M Lammens; M Huizing; G W Padberg; R A Wevers; B G van Engelen; D J Lefeber
Journal:  Clin Neuropathol       Date:  2010 Mar-Apr       Impact factor: 1.368

2.  Sialic acid deficiency is associated with oxidative stress leading to muscle atrophy and weakness in GNE myopathy.

Authors:  Anna Cho; May Christine; V Malicdan; Miho Miyakawa; Ikuya Nonaka; Ichizo Nishino; Satoru Noguchi
Journal:  Hum Mol Genet       Date:  2017-08-15       Impact factor: 6.150

3.  Activation of the Unfolded Protein Response in Sporadic Inclusion-Body Myositis but Not in Hereditary GNE Inclusion-Body Myopathy.

Authors:  Anna Nogalska; Carla D'Agostino; W King Engel; Mafalda Cacciottolo; Shinichi Asada; Kazutoshi Mori; Valerie Askanas
Journal:  J Neuropathol Exp Neurol       Date:  2015-06       Impact factor: 3.685

4.  GNE Myopathy and Cell Apoptosis: A Comparative Mutation Analysis.

Authors:  Reema Singh; Ranjana Arya
Journal:  Mol Neurobiol       Date:  2015-05-15       Impact factor: 5.590

5.  Sialyllactose ameliorates myopathic phenotypes in symptomatic GNE myopathy model mice.

Authors:  Takahiro Yonekawa; May Christine V Malicdan; Anna Cho; Yukiko K Hayashi; Ikuya Nonaka; Toshiki Mine; Takeshi Yamamoto; Ichizo Nishino; Satoru Noguchi
Journal:  Brain       Date:  2014-07-24       Impact factor: 13.501

6.  Deficits in sialylation impair podocyte maturation.

Authors:  Birgit Weinhold; Melanie Sellmeier; Wiebke Schaper; Linda Blume; Brigitte Philippens; Elina Kats; Ulrike Bernard; Sebastian P Galuska; Hildegard Geyer; Rudolf Geyer; Kirstin Worthmann; Mario Schiffer; Stephanie Groos; Rita Gerardy-Schahn; Anja K Münster-Kühnel
Journal:  J Am Soc Nephrol       Date:  2012-06-28       Impact factor: 10.121

7.  Prophylactic treatment with sialic acid metabolites precludes the development of the myopathic phenotype in the DMRV-hIBM mouse model.

Authors:  May Christine V Malicdan; Satoru Noguchi; Yukiko K Hayashi; Ikuya Nonaka; Ichizo Nishino
Journal:  Nat Med       Date:  2009-06       Impact factor: 53.440

8.  Ganglioside GM3 levels are altered in a mouse model of HIBM: GM3 as a cellular marker of the disease.

Authors:  Thomas Paccalet; Zoé Coulombe; Jacques P Tremblay
Journal:  PLoS One       Date:  2010-04-07       Impact factor: 3.240

9.  Safety and in vivo expression of a GNE-transgene: a novel treatment approach for hereditary inclusion body myopathy-2.

Authors:  Anagha P Phadke; Chris Jay; Salina J Chen; Courtney Haddock; Zhaohui Wang; Yang Yu; Derek Nemunaitis; Gregory Nemunaitis; Nancy S Templeton; Neil Senzer; Phillip B Maples; Alex W Tong; John Nemunaitis
Journal:  Gene Regul Syst Bio       Date:  2009-05-08

10.  Preclinical assessment of wt GNE gene plasmid for management of hereditary inclusion body myopathy 2 (HIBM2).

Authors:  Chris Jay; Gregory Nemunaitis; John Nemunaitis; Neil Senzer; Stephan Hinderlich; Daniel Darvish; Julie Ogden; John Eager; Alex Tong; Phillip B Maples
Journal:  Gene Regul Syst Bio       Date:  2008-06-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.